Picture courtesy Twitter
Pune: Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) and Union Health ministry for full market authorization of its COVID-19 vaccine Covishield.
Adar Poonawalla, the CEO of SII, tweeted on Friday that the Indian government now has enough data to consider a full market authorization of Oxford-AstraZeneca’s COVID which is produced under the brand name Covishield by the Pune-based firm.
Once the drug regulator and government give the go-ahead, Covishield will be available in medical stores.
Since being approved by DGCI for emergency use in January 2021, Covishield along with Bharat Biotech’s indigenously manufactured Covaxin has been used in India’s massive inoculation programme.
SII, the world’s biggest vaccine maker, has till date supplied over 1.25 billion doses of Covishield, which most Indians have received.
SII currently makes 240 million doses per month and is ready to export ‘large volumes’ from January, Poonawalla told Reuters.
Mumbai: The first day of the IPL mega player auction at Jeddah threw up several…
Bhubaneswar: The Odisha government has handed over the investigation into the attack on Dhramasala MLA…
Bhubaneswar: The Commissionerate of Police on Sunday issued an advisory for movement of vehicular traffic…
New York: Now that President-elect Donald Trump has tasked Elon Musk with the responsibility of co-heading…
Bhubaneswar: The Odisha government has warned its employees of stern action for sub-letting their allotted…
Mumbai: There has been a lot of talk over AR Rahman and his wife Saira…
Sundargarh: The North Odisha Development Council (NODC) would be formed in 2-3 months, said Chief…
Puri: Director General of Police (DGP) YB Khurania on Sunday reviewed the security arrangements for…